Cytokinetics to Hold Annual Meeting of Stockholders
May 10 2018 - 4:00PM
Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that its
Annual Meeting of Stockholders will be held on Wednesday, May 16,
2018 at 10:30 AM Pacific Time at the Embassy Suites Hotel, located
at 250 Gateway Boulevard in South San Francisco, CA. Robert I.
Blum, President and Chief Executive Officer, is scheduled to
present an overview of Cytokinetics’ performance.
Interested parties may access the live webcast
of this presentation by visiting the Investors & Media section
of Cytokinetics’ website at www.cytokinetics.com. The live audio of
the conference call can also be accessed by telephone by dialing
either (866) 999-CYTK (2985) (United States and Canada) or (706)
679-3078 (international) and typing in the passcode 1990098.
An archived replay of the webcast will be
available via Cytokinetics’ website until May 23, 2018. The replay
will also be available via telephone by dialing (855) 859-2056
(United States and Canada) or (404) 537-3406 (international) and
typing in the passcode 1990098 from May 16, 2018 at 1:30 PM Pacific
Time until May 23, 2018.
About Cytokinetics
Cytokinetics is a late-stage
biopharmaceutical company focused on discovering, developing and
commercializing first-in-class muscle activators as potential
treatments for debilitating diseases in which muscle performance is
compromised and/or declining. As a leader in muscle biology and the
mechanics of muscle performance, the company is developing small
molecule drug candidates specifically engineered to increase muscle
function and contractility. Cytokinetics is collaborating
with Amgen Inc. (“Amgen”) to develop omecamtiv
mecarbil, a novel cardiac muscle activator. Omecamtiv
mecarbil is the subject of GALACTIC-HF, an international Phase
3 clinical trial in patients with heart
failure. Amgen holds an exclusive worldwide license to
develop and commercialize omecamtiv mecarbil with a
sublicense held by Servier for commercialization
in Europe and certain other
countries. Cytokinetics is collaborating
with Astellas Pharma Inc. (“Astellas”) to
develop reldesemtiv (CK-2127107), a next-generation fast
skeletal muscle troponin activator
(FSTA). Reldesemtiv has been granted orphan drug
designation by the FDA for the potential treatment of
spinal muscular atrophy. Reldesemtiv is the subject of
three ongoing Phase 2 clinical trials enrolling patients with
spinal muscular atrophy, chronic obstructive pulmonary disease and
amyotrophic lateral sclerosis. Astellas is also conducting a Phase
1b clinical trial of reldesemtiv in elderly adults with
limited mobility. Astellas holds an exclusive worldwide license to
develop and commercialize reldesemtiv. Licenses held
by Amgen and Astellas are subject
to Cytokinetics' specified co-development and
co-commercialization rights. Cytokinetics continues its
20-year history of innovation with three new muscle biology
directed compounds advancing from research to development in 2018.
For additional information about Cytokinetics,
visit www.cytokinetics.com.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any intent or
obligation to update these forward-looking statements, and claims
the protection of the Act's Safe Harbor for
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating to Cytokinetics' and
its partners' research and development activities of Cytokinetics’
product candidates. Such statements are based on management's
current expectations, but actual results may differ materially due
to various risks and uncertainties, including, but not limited to
the risks related to Cytokinetics' business outlined in
Cytokinetics' filings with the Securities and Exchange
Commission. Forward-looking statements are not guarantees of future
performance, and Cytokinetics' actual results of operations,
financial condition and liquidity, and the development of the
industry in which it operates, may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that Cytokinetics makes in this press
release speak only as of the date of this press release.
Cytokinetics assumes no obligation to update its forward-looking
statements whether as a result of new information, future events or
otherwise, after the date of this press release.
Contact:CytokineticsDiane WeiserVice President,
Corporate Communications, Investor Relations(650) 624-3060
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024